Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis

Arthritis Research and Therapy

Volumn 14, Issue 3, 2012, Pages

  Burr, Marian L ^a,b   Viatte, Sebastien ^a   Bukhari, Marwan ^a   Plant, Darren ^a   Symmons, Deborah P ^a   Thomson, Wendy ^a   Barton, Anne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; DIAGNOSTIC AGENT;

ACCURACY; ADULT; ANTIBODY TITER; ARTICLE; BONE EROSION; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN TISSUE; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYARTHRITIS; PRIMARY MEDICAL CARE; PROGNOSIS; RISK; SEROCONVERSION; BLOOD; IMMUNOLOGY; MIDDLE AGED; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS;

EID: 84860866432     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3834     Document Type: Article

References (27)

1. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O. The need for prognosticators in rheumatoid arthritis: biological and clinical markers: where are we now?. Arthritis Res Ther 2008, 10:208. 10.1186/ar2418, 2483438, 18557991.
2. Riedemann JP, Munoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis: a systematic review. Clin Exp Rheumatol 2005, 23:S69-S76.
3. van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005, 64:1510-1512. 10.1136/ard.2004.035089, 1755241, 15800005.
4. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004, 63:1090-1095. 10.1136/ard.2003.014233, 1755129, 15308518.
5. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, van der HD, Landewe R, Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217. 10.1136/ard.2006.068247, 17526555.
6. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007, 46:342-349.
7. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005, 64:196-201. 10.1136/ard.2003.019992, 1755350, 15458956.
8. Farragher TM, Lunt M, Plant D, Bunn DK, Barton A, Symmons DP. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies. Arthritis Care Res (Hoboken) 2010, 62:664-675.
9. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, Beynon R, Ben-Shlomo Y, Axford J, Dieppe P. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010, 152:456-464.
10. Ursum J, Bos WH, van de Stadt RJ, Dijkmans BA, van SD. Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems. Arthritis Res Ther 2009, 11:R75. 10.1186/ar2704, 2714121, 19460147.
11. Nielen MM, van SD, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004, 50:380-386. 10.1002/art.20018, 14872479.
12. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749. 10.1002/art.11223, 14558078.
13. Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol 2009, 36:706-711. 10.3899/jrheum.080895, 3108039, 19228654.
14. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 2011, 50:311-316.
15. Nell-Duxneuner V, Machold K, Stamm T, Eberl G, Heinzl H, Hoefler E, Smolen JS, Steiner G. Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study. Ann Rheum Dis 2010, 69:169-174. 10.1136/ard.2008.100677, 19153104.
16. Ursum J, Bos WH, van DN, Dijkmans BA, van SD. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010, 12:R8. 10.1186/ar2907, 2875634, 20064278.
17. Ronnelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005, 64:1744-1749. 10.1136/ard.2004.033571, 1755292, 15843452.
18. Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 2006, 8:R40. 10.1186/ar1896, 1526612, 16469118.
19. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089. 10.1136/ard.2003.016808, 1755123, 15308517.
20. Harrison B, Thomson W, Symmons D, Ollier B, Wiles N, Payton T, Barrett E, Silman A. The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 1999, 42:2174-2183. 10.1002/1529-0131(199910)42:10<2174::AID-ANR19>3.0.CO;2-G, 10524690.
21. http://www.das-score.nl/www.das-score.nl
22. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977, 18:481-491.
23. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002, 46:906-912. 10.1002/art.10167, 11953966.
24. Ho PY, Barton A, Worthington J, Thomson W, Silman AJ, Bruce IN. HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 2007, 66:807-811. 10.1136/ard.2006.064972, 1954651, 17223660.
25. Bukhari M, Thomson W, Naseem H, Bunn D, Silman A, Symmons D, Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007, 56:2929-2935. 10.1002/art.22868, 2435419, 17763407.
26. Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:427-430. 10.1136/ard.62.5.427, 1754544, 12695154.
27. Mjaavatten MD, Heijde DV, Uhlig T, Haugen AJ, Nygaard H, Sidenvall G, Helgetveit K, Kvien TK. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res Ther 2010, 12:R76. 10.1186/ar2995, 2911852, 20444271.